A Phase 4 interventional study of Dexamethasone and Vincristine in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma and Mixed Phenotype Acute Leukemia, sponsored by St. Jude Children's Research Hospital. Recruiting at 5 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by St. Jude Children's Research Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 11 open to participants now, 19 under way, 6 of them phase 3. Dexamethasone · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 7th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 4, reaches primary completion later than 18 of the 18 other live ones, and was the 61st registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →11 of the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
Hee Young Ju · Sites in Korea, Republic of
Ages 1–9
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 12 more countries
Ages 1–21
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31 · Phase 3 15 · Phase 4 6
First in 1990; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 850 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 49 across the 62 interventional studies. Of the 39 that completed or were terminated, 16 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 63 have an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital: 15 open now, 25 under way, 1 of them phase 3. Of 44 finished, 17 (39%) have results posted.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one has the largest planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 in phase 4, reaches primary completion later than 24 of the 24 other live ones, and was the 58th registered.
St. Jude Children's Research Hospital’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 1993.
4 of the studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681260Phase 3Children's Cancer Group, ChinaCapizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) | 2026-12-31 |
| NCT05495035Institute of Hematology & Blood Diseases Hospital, ChinaStudy for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | 2026-12-31 |
| NCT02494882Memorial Sloan Kettering Cancer CenterAdding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | 2027-06 |
| NCT03136146M.D. Anderson Cancer CenterCombination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | 2027-08-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among St. Jude Children's Research Hospital’s 70 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment.
Primary Objectives
Secondary Objectives
Patients with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL/LLy) and mixed phenotype acute leukemia/lymphoma (MPAL) will undergo diagnostic procedures either during screening or on Day 1. They will receive 7 days of chemotherapy including 13 doses of dexamethasone, 1 dose of vincristine, and 1 dose of daunorubicin (for patients with T-ALL/LLy or MPAL only). Patients will also undergo their initial lumbar puncture with intrathecal chemotherapy on Days 4 or 5 or 6 of therapy. After the completion of 7 days of chemotherapy, patients will begin therapy on either a SJALL therapeutic trial or will receive non-protocol therapy.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of acute leukemia / lymphoma as below:
Exclusion Criteria:
Note: The intention of this exclusion criterion is to enroll all newly diagnosed ALL/ LLy/ MPAL patients. If participant is screened as a potential participant for subsequent SJALL and later found to be ineligible due to information obtained during INITIALL, this will not make the participant ineligible for INITIALL.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible patients receive the following intervention: Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Dexamethasone · Drug: Vincristine · Drug: Daunorubicin · Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) · Drug: Methotrexate · Drug: Cytarabine
Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
Also known as: Decadron
Intravenously (IV) for 1 dose on Day 1 or 2
Also known as: Vincristine Sulfate, Oncovin
Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
Also known as: Daunomycin
Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
Also known as: ITMHA
Given IT as part of Intrathecal triple therapy.
Also known as: MTX, Trexall®
Given IT as part of Intrathecal triple therapy.
Also known as: Cytosine arabinoside, Ara-C
Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy).
The proportion of patients with sufficient immunophenotypic, genomic, and clinical data to allow determination of eligibility for currently open trials at the enrolling institution.
Time frame: 1 week from study entry
Complete data within the INITIALL database
The proportion of patients with complete data within the INITIALL protocol database as described in the protocol.
Time frame: 3 months, 1 year, 3, 5 years from study entry
Event Free Survival (EFS)
EFS will be reported as estimates using the Kaplan-Meier method.
Time frame: 1, 3, 5 years from study entry
Overall Survival (OS)
OS will be reported as estimates using the Kaplan-Meier method.
Time frame: 1, 3, 5 years from study entry
Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available at the time of article publication.
Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Started Dec 2024 (actual). Primary completion is estimated for May 2034, 113 months after the start.
Of 30 phase 4 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 123. This study's planned 113 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Vincristine · Daunorubicin · Methotrexate · Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
St. Jude Children's Research Hospital →